Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study-right-to-reply
Journal of Antimicrobial Chemotherapy · 03.06.2026 · 81 (7)
DOI: 10.1093/jac/dkag209 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 11.06.2026. Verfasst von Jumpei Taniguchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. Die Arbeit nennt 1 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
We thank González et al.1 for their interest in our study and for their thoughtful comments. First, we performed an additional analysis of hospital length of stay. After overlap weighting, the mean length of stay was 17.4 days [95% confidence interval (CI), 17.3–17.5] in the ceftriaxone 2 g/day group and 18.1 days (95% CI, 18.0–18.3) in the ceftriaxone 1 g/day group. The adjusted mean difference was −0.7 days (95% CI, −0.9 to −0.5). Although this difference was statistically significant, the absolute difference was not clinically meaningful. These findings do not materially alter the overall interpretation of our study1. Furthermore, because hospital length of stay in Japan is generally longer than that in many Western countries owing to differences in healthcare systems, these findings may not be directly generalizable to other healthcare settings. With regard to patients discharged within 2 days, we excluded these patients to ensure adequate exposure to the initial treatment strategy and to define a clinically relevant target population. Accordingly, these patients were outside the population for which treatment effects were estimated in our study. Furthermore, discharge within 2 days was only one of the several eligibility criteria used to define the analytic cohort. Therefore, descriptive analyses limited to patients excluded solely on this basis would be difficult to interpret and of limited value in informing the treatment effect estimates reported in the study.
Autor:innen und Institutionen
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
- Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Jumpei Taniguchi
Förderung
- Ministry of Health, Labour and Welfare
Zitieren
APA
Taniguchi, J., Aso, S., & Yasunaga, H. (2026). Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study-right-to-reply. Journal of Antimicrobial Chemotherapy, 81(7). https://doi.org/10.1093/jac/dkag209
Vancouver
Taniguchi J, Aso S, Yasunaga H. Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study-right-to-reply. Journal of Antimicrobial Chemotherapy. 2026;81(7). doi:10.1093/jac/dkag209
BibTeX
@article{Taniguchi2026,
author = {Taniguchi, Jumpei and Aso, Shotaro and Yasunaga, Hideo},
title = {Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study-right-to-reply},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {7},
doi = {10.1093/jac/dkag209}
}
EUVIMED